Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

The 20-year deal with Constellation Energy would kick-start the site of the nation's worst nuclear accident. Top-end German carmakers have joined expensive French handbags among the products hit by ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Organon (OGN – Research Report) today. The company’s shares opened ...

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...

The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older ...

Eli Lilly and Co. ($LLY) announced that the U.S. Food and Drug Administration (FDA) had approved its atopic dermatitis ...

On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and ... The drug is ...

This roundup covers various health news highlights including the mpox outbreak in Africa and vaccine distribution issues, the ...

Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above ...